“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcomePatrizia Vici, Filippo Montemurro, Laura Pizzuti et al.|Oncotarget|2016Cited by 43
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world settingLaura Pizzuti, Nicola Tinari, Eriseld Krasniqi et al.|Therapeutic Advances in Medical Oncology|2021Cited by 10
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational studyFrancesca Sofia Di Lisa, Enzo Veltri, Eriseld Krasniqi et al.|Frontiers in Oncology|2023Cited by 9
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)Rosalba Torrisi, Armando Santoro, Raffaella Palumbo et al.|Breast Cancer Research and Treatment|2021Cited by 4
Fulvestrant administered in two different schedules: Pharmacokinetics, biological markers, and activity.A. Felici, Paola Papaldo, Asha Tata et al.|Journal of Clinical Oncology|2011Cited by 0